Applied Biosystems has announced the acquisition of the research products division of Ambion, a supplier of RNA-based reagents for life science research and drug development, subject to conditions
Ambion's sample prep, RNAi, microRNA, and gene expression and array products give will Applied Biosystems a new foothold in this fast-growing market and will represent a significant growth in its consumables product offering.
Ambion develops and supplies innovative consumable products for stabilising, synthesising, handling, isolating, storing, detecting and quantifying RNA.
Recent product introductions include cutting-edge microRNA and siRNA reagents used to study mechanisms of gene expression that could lead to advances in human healthcare.
Ambion's products will allow Applied Biosystems to offer customers more complete workflows, and the RNA R+D expertise and consumables manufacturing capabilities will complement Applied Biosystems's own existing strengths.
Ambion's research and development, manufacturing, and other operations will continue to be based in Austin, Texas, reporting to the molecular biology division of Applied Biosystems.
Ambion's diagnostics and service businesses will become a separate standalone company.
